CGON vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGON Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Momentum & Technical, Options & Structure while FDMT counters with relative strength in Growth & Margin. Fundamentally, CGON trades at N/M Forward P/E with -4293.5% operating margin (-3.7% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGON Revenue | FDMT Revenue | CGON Op. Margin | FDMT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -729.4% | FDMT |
| FY2020 | N/A | $10M | N/A | -424.0% | FDMT |
| FY2021 | N/A | $20M | N/A | -395.5% | FDMT |
| FY2022 | N/A | $0M | N/A | -3516.5% | FDMT |
| FY2023 | $0M | $20M | -27180.9% | -544.6% | FDMT |
| FY2024 | $0M | $0M | -10067.3% | -507678.4% | CGON |
| FY2025 | $0M | $90M | -4722.1% | -187.2% | FDMT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGON | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.3B | $669.3M | Larger Scale | CGON |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -3.7% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -4293.5% | -222.7% | Higher Margin | FDMT |
| Net Profit Margin Profitability | 0.0% | -208.6% | Higher Margin | CGON |
| Return on Equity (ROE) Capital Efficiency | -28.3% | -56.7% | Higher ROE | CGON |
| 52-Week Range Position Momentum | 84% ($37โ$94) | 45% ($7โ$17) | Stronger Trend | CGON |
| Beta / 30D Volatility Risk Regime | 0.77ฮฒ ยท 86% Vol | 1.90ฮฒ ยท 91% Vol | Lower Realized Risk | CGON |
| Unified Institutional Score Composite Signal | 45.0 / 100 (HOLD) | 51.3 / 100 (HOLD) | Higher Composite | FDMT |